Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Uridine Triacetate in Pediatric Hereditary Orotic Aciduria
NCT02110147Phase 3Completed
- Sponsor
- Wellstat Therapeutics Corporation
- Start
- Apr 2014
- Primary completion
- Dec 2014
- Modality
- Nucleic Acid-Directed Small Molecules, Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of uridine triacetate in hereditary orotic aciduria (HOA), sponsored by Wellstat Therapeutics Corporation. Started Apr 2014; status: completed.
02
Drugs
uridine triacetate
03
Conditions
hereditary orotic aciduria (HOA)
Beyond the preview
Go deeper on NCT02110147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02110147.